摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(4-[(9-Fluoro-4,5-dihydrobenzo[2,3]thiepino[4,5-d][1,3]thiazol-2-yl)amino]methylcyclohexyl)-N-isopropylformamide | 304006-88-0

中文名称
——
中文别名
——
英文名称
N-(4-[(9-Fluoro-4,5-dihydrobenzo[2,3]thiepino[4,5-d][1,3]thiazol-2-yl)amino]methylcyclohexyl)-N-isopropylformamide
英文别名
N-[4-[[(9-fluoro-4,5-dihydro-[1]benzothiepino[5,4-d][1,3]thiazol-2-yl)amino]methyl]cyclohexyl]-N-propan-2-ylformamide
N-(4-[(9-Fluoro-4,5-dihydrobenzo[2,3]thiepino[4,5-d][1,3]thiazol-2-yl)amino]methylcyclohexyl)-N-isopropylformamide化学式
CAS
304006-88-0
化学式
C22H28FN3OS2
mdl
——
分子量
433.614
InChiKey
VPQKCEMSBBADCT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.5
  • 重原子数:
    29
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    98.8
  • 氢给体数:
    1
  • 氢受体数:
    6

文献信息

  • Selective NPY (Y5) antagonists
    申请人:Marzabadi R. Mohammad
    公开号:US20050176709A1
    公开(公告)日:2005-08-11
    This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.
    本发明涉及三嗪衍生物双环化合物三环化合物,它们是选择性 Y5 受体拮抗剂。该发明提供一种药物组合物,包括本发明化合物的治疗有效量和药学上可接受的载体。本发明提供一种药物组合物,由本发明化合物的治疗有效量和药学上可接受的载体组成。本发明提供一种制备药物组合物的方法,包括将本发明化合物的治疗有效量和药学上可接受的载体混合。本发明还提供一种使用本发明化合物制备药物组合物的方法,用于治疗异常情况,其中通过降低人类 Y5 受体的活性来缓解异常情况。
  • TRIAZINE DERIVATIVES FOR USE AS SELECTIVE NPY (Y5) ANTAGONISTS
    申请人:H. LUNDBECK A/S
    公开号:EP1816127A1
    公开(公告)日:2007-08-08
    This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.
    本发明涉及三嗪衍生物双环化合物三环化合物,它们是 NPY(Y5)受体的选择性拮抗剂。本发明提供了一种药物组合物,其中包含治疗有效量的本发明化合物和药学上可接受的载体。本发明提供了一种由治疗有效量的本发明化合物和药学上可接受的载体组合而成的药物组合物。本发明提供了一种制备药物组合物的工艺,该工艺包括将治疗有效量的本发明化合物与药学上可接受的载体相结合。本发明进一步提供了本发明化合物用于制备治疗异常的药物组合物的用途,其中通过降低人Y5受体的活性来缓解异常。
  • SELECTIVE NPY (Y5) ANTAGONISTS
    申请人:H. LUNDBECK A/S
    公开号:EP1183245B1
    公开(公告)日:2007-05-09
  • US6124331A
    申请人:——
    公开号:US6124331A
    公开(公告)日:2000-09-26
  • US6989379B1
    申请人:——
    公开号:US6989379B1
    公开(公告)日:2006-01-24
查看更多